Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Idiopathic Pulmonary Fibrosis Market Size, Value And Growth Trends Through 2030
The market for idiopathic pulmonary fibrosis has experienced robust expansion recently, projected to increase from $4.37 billion in 2025 to $4.66 billion in 2026, reflecting a compound annual growth rate of 6.7%. This historical growth trajectory is linked to a scarcity of therapeutic interventions for fibrotic lung conditions, a growing elderly demographic, enhanced awareness and diagnosis of IPF, the introduction of nintedanib and pirfenidone, and a greater emphasis on inpatient care for chronic respiratory ailments.
The global idiopathic pulmonary fibrosis market is projected for significant expansion over the coming years, anticipated to reach a valuation of $6.16 billion by the year 2030. This substantial growth will occur at a compound annual growth rate of 7.2%. Several key factors are expected to fuel this upward trajectory during the forecast period, including augmented investment in pulmonary fibrosis research, the advent of advanced antifibrotic medications, a greater reliance on real-world data to guide treatment choices, the broadening reach of online and specialized pharmacy services, and heightened public awareness surrounding uncommon respiratory ailments. Prominent developments shaping this market outlook encompass a greater embrace of antifibrotic treatments, an intensified emphasis on achieving prompt and precise diagnoses, a growing tendency to employ combination drug regimens, a wider implementation of remote and sustained disease management strategies, and an increased involvement in clinical studies for innovative therapeutic approaches.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12579&type=smp
Idiopathic Pulmonary Fibrosis Market Industry Drivers: What Is Driving Revenue Growth?
The expanding demographic of elderly individuals is poised to stimulate the expansion of the idiopathic pulmonary fibrosis market. This demographic encompasses senior citizens, and the natural aging process brings about changes in lung structure and function, rendering them more prone to respiratory ailments like IPF, thereby elevating the demand for relevant therapies. Notably, projections from the Population Reference Bureau in January 2024 indicate a significant surge in the American elderly population, anticipated to climb from 58 million in 2022 to 82 million by 2050, representing a 47% increase, and consequently, their share of the total U.S. population will increase from 17% to 23% over the same timeframe, underlining how the growing elderly segment fuels the IPF market.
Idiopathic Pulmonary Fibrosis Market Segment Analysis Highlighting Growth Areas
The idiopathic pulmonary fibrosis market covered in this report is segmented –
1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types
2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers
5) By End Users: Hospitals And Clinics, Other End Users
Subsegments:
1) By Nintedanib: Indications, Dosage Forms, Administration Routes
2) By Pirfenidone: Indications, Dosage Forms, Administration Routes
3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies
#Idiopathic Pulmonary Fibrosis Market Growth Trends: What Is Influencing The Future Outlook?
Key players within the idiopathic pulmonary fibrosis (IPF) arena are strategically concentrating on the development of novel therapies, specifically anti-fibrotic small-molecule inhibitors, as a means to solidify their market standing. These inhibitors represent a class of drugs engineered to counteract the fibrotic pathways implicated in the disease. A notable development occurred in June 2023 when Insilico Medicine, a US-based biotechnology firm specializing in generative artificial intelligence (AI), commenced Phase II clinical investigations for INS018_055. This particular compound holds the distinction of being the inaugural anti-fibrotic small molecule inhibitor discovered using generative AI technology. The commencement of administering the first dose to trial participants signifies a significant step forward. The trial itself is designed as a randomized, double-blind, placebo-controlled study intended to assess the safety profile, patient tolerance, pharmacokinetic properties, and initial effectiveness of a twelve-week oral regimen of INS018_055 in individuals diagnosed with idiopathic pulmonary fibrosis (IPF). This pioneering methodology highlights the transformative potential of AI in the process of drug discovery, signifying a promising advancement in the therapeutic landscape for IPF conditions.
Idiopathic Pulmonary Fibrosis Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the idiopathic pulmonary fibrosis market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.
Access The Complete Idiopathic Pulmonary Fibrosis Market Report:
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
Idiopathic Pulmonary Fibrosis Market Regional Analysis: Which Region Leads By Revenue?
North Americawas the largest region in the idiopathic pulmonary fibrosis market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
